Central venulitis in pediatric liver allografts

被引:39
作者
Krasinskas, AM
Ruchelli, ED
Rand, EB
Chittams, JL
Furth, EE
机构
[1] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA
[4] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[5] Childrens Hosp Philadelphia, Div Pediat Gastroenterol, Philadelphia, PA 19104 USA
关键词
D O I
10.1053/jhep.2001.23938
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Central venulitis (CV), a distinct histologic lesion described in adult liver transplants, can occur with acute portal tract rejection or in isolation (ICV). Possible etiologies include immunosuppressive drag toxicity, acute cellular rejection, viral hepatitis, ischemic injury, and recurrent disease. This study was designed to characterize ICV and to assess its potential etiology in pediatric liver recipients because this population generally does not develop recurrent disease or viral hepatitis. All posttransplantation liver biopsy specimens that were obtained from children who received liver allografts over a 4-year period were reviewed. ICV was identified in 12 of 127 posttransplantation biopsies and in 7 of 45 allograft recipients. Only 4 liver transplantations were performed for potentially recurrent diseases (primary sclerosing cholangitis). ICV first appeared in posttransplantation biopsy specimens significantly later than did portal rejection alone. The finding of CV was not significantly correlated with elevation of Tacrolimus levels, reason for transplantation, donor/recipient cytomegalovirus (CMV) status or blood type, cold ischemic times, or the incidence of outflow obstruction. The responses of CV to therapy were variable and, although the majority of cases resolved, several episodes persisted or recurred. In conclusion, ICV occurs in 16% of pediatric liver allograft recipients and does not appear to be related to recurrent disease, viral hepatitis, drug toxicity, or graft ischemia. CV may be a variant of acute rejection, but longer follow-up is required to determine the most adequate therapy for this entity.
引用
收藏
页码:1141 / 1147
页数:7
相关论文
共 21 条
[1]   Prognostic implications of centrilobular necrosis in pediatric liver transplant recipients [J].
Allen, KJ ;
Rand, EB ;
Hart, J ;
Whitington, PF .
TRANSPLANTATION, 1998, 65 (05) :692-698
[2]  
Demetris A, 2000, Hepatology, V31, P792
[3]  
Demetris AJ, 1997, HEPATOLOGY, V25, P658
[4]  
DEMETRIS AJ, 1991, AM J PATHOL, V138, P618
[5]  
DHILLON AP, 1994, HEPATOLOGY, V19, P106
[6]  
FISHER A, 1995, TRANSPLANTATION, V59, P1631
[7]   Liver transplantation for primary sclerosing cholangitis [J].
Gow, PJ ;
Chapman, RW .
LIVER, 2000, 20 (02) :97-103
[8]   FK506 VERSUS CYCLOSPORINE AS PRIMARY IMMUNOSUPPRESSIVE AGENT FOR ORTHOTOPIC LIVER ALLOGRAFT RECIPIENTS - HISTOLOGIC AND IMMUNOPATHOLOGIC OBSERVATIONS [J].
HYTIROGLOU, P ;
LEE, R ;
SHARMA, K ;
THEISE, ND ;
SCHWARTZ, M ;
MILLER, C ;
THUNG, SN .
TRANSPLANTATION, 1993, 56 (06) :1389-1394
[9]   Central venulitis in the allograft liver: Immunosupression toxicity or cellular rejection variant? [J].
Krasinskas, AM ;
Stewart, CA ;
Furth, E ;
Lucey, MR ;
Shaked, A ;
Olthoff, KM ;
Nunes, FA ;
Markmann, JF ;
Zeldin, GA .
TRANSPLANTATION, 1999, 67 (09) :S636-S636
[10]   PERSISTENT CENTRILOBULAR NECROSES IN HEPATIC ALLOGRAFTS [J].
LUDWIG, J ;
GROSS, JB ;
PERKINS, JD ;
MOORE, SB .
HUMAN PATHOLOGY, 1990, 21 (06) :656-661